Based on the success of our last years’ events, we have started to prepare our next, 4th Annual Biosimilars Forum, will be held on 17-18 OCT., 2019 in Budapest.
Next forum will cover actual issues and specific areas of debate facing clinical development teams for biosimilars with a strong focus on statistical and regulatory perspectives. As in previous years, the program of the event will be supported and complemented by international subject experts from the biosimilars and nanomedicines area. The detailed program will be available soon, until then we recommend you read more about our previous forums below!
At the Annual Biosimilars Forum event series, clinicians, statisticians and regulatory representatives gathered together from around the world to share with each other their perspectives on this key topic of research. Some topics of the last three year’s forums included:
2016 OCT: 1st Annual Biosimilars Forum | Lecture examples:
2017 OCT: 2nd Annual Biosimilars Forum | Lecture examples:
2018 OCT: 3rd Annual Biosimilars Forum | Lecture examples:
Bring the Regulators and Producer Companies together into one room is an excellent idea and a beautiful concept.
–Bernd JILMA | Vice Chair, Department Clinical Pharmacology, Medical University of Vienna
I think it’s very nicely covers the whole biosimilar development process… Broader roles could benefit from this conference!
–Ildikó ARADI | Head of Clinical Development of Biologics, Gedeon Richter Plc.
These conferences are extremely useful, they provide discussions in many problems and issues. I hope very much that the series will continue …
–László ENDRÉNYI | Professor Emeritus of Pharmacology and Biostatistics, University of Toronto
The Organizers really done a very good job trying to put together such a conference where we can exchange an idea regarding the regulatory approval process and also on some actual issues in the biosimilar drug development process.
–Shein-Chung CHOW | Professor, Duke University School of Medicine
These meetings, where experts are coming together from the same or different countries bring something new: collaborations, new knowledge, so this is very precious.
–János SZEBENI | Director of the Nanomedicine Research and Education Center at Semmelweis University